Camurus (CAMRF) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of the New Drug Application for Oclaiz, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act target action date of 10 June 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMRF:
- Camurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing
- Camurus Increases Share Capital After Employee Stock Option Exercise
- Camurus Increases Shares and Votes Following Employee Stock Option Exercise
- Camurus Announces Nomination Committee for AGM 2026
- Camurus AB Earnings Call: Growth Amid Challenges